Document:

EX-10.10

 Exhibit 10.10 

GENELUX CORPORATION CONSULTING AGREEMENT 

THIS AGREEMENT is made and entered into effective as of the 1st day of September, 2011 (the “Effective Date”), by and between
Genelux Corporation, a Delaware corporation (the “Company”), and Pharmaceutical Research Consulting (PRC) (“Consultant”). 

W I T N E S S ET H: 
 WHEREAS,
the Company wishes to retain Consultant as an independent contractor to perform certain consulting services; and 
 WHEREAS, Consultant is
willing to perform such services for the consideration and on the terms set forth in this Agreement; 
 NOW, THEREFORE, in consideration of
the premises and the mutual promises set forth below, the parties agree as follows: 
 1.    Engagement. 

(a)    Scope of Work. Consultant shall perform the work described in Exhibit A attached hereto and such other work
as may be mutually agreed upon by the Company and Consultant (the “Work”). Consultant shall perform the Work under the direction of the President of the Company or such other person(s) as the Company may designate. During the term
of this Agreement, Consultant shall use Consultant’s best efforts in performing the Work. Except as otherwise agreed upon by the Company in writing, all of the Work under this Agreement shall be performed by Paul Scigalla, M.D., Ph.D. 

(b)    Professional Standards. The manner and means used by Consultant to achieve the result desired by the Company
are in the sole discretion and control of Consultant. Consultant’s results will be the product of the highest degree of professional skill and expertise. 

(c)    Location. Consultant shall provide services at places which in his judgment are best suited to accomplish
the projects in a timely and professional manner consistent with industry standards. Consultant agrees to attend meetings and presentations at the Company’s facility as may be requested by the Company from time to time. Consultant agrees not to
remove from the Company’s premises any Company-owned hardware, software, or other equipment or property, without the prior written consent of the Company. 

2.    Compensation. In consideration for the services and the terms of this Agreement, Consultant shall be paid the
following compensation: 
 (a)    The Company agrees to pay Consultant three hundred forty U.S. dollars ($340) per hour
for services performed in accordance with this Agreement, up to a maximum of two thousand seven hundred twenty U.S. dollars ($2720) per day. During any day when Consultant works from home at the request of the Company, he will perform a minimum of
two (2) hours of Work per day and be entitled for compensation for a minimum of two (2) hours of Work per day. Consultant agrees, at the Company’s request, to work at the Company’s San Diego office as the Company shall from time
to time designate, for which Consultant will be paid a flat daily fee of $2,720, and which shall reflect nine (9) hours of work. From time to time, the Company may also request that Consultant participate in investigator meetings or scientific
meetings such as ASN, ASCO or EDTA, the time for which shall be billed as set forth hereinabove. 

  
 1 

Confidential 

 CONSULTING AGREEMENT 

 

 (b)    In addition to payment for services provided, the Company shall
also reimburse Consultant for pre-approved out-of-pocket expenses incurred directly in the performance of services under this
Agreement, including overnight mailing, facsimile transmissions, authorized telephone charges, including those associated with e-mail use, and authorized hotel expenses. Further, the Company agrees to
reimburse Contractor for pre-approved travel expenses incurred directly in the performance of services under this Agreement, including business-class travel on both domestic and international flights in accordance with Company policy, after the
Company’s receipt and approval of monthly expense reports documenting all such expenses in reasonable detail. 

3.    Consultant’s Warranties. 

(a)    Consultant acknowledges and agrees that Consultant’s performance of the Work hereunder does not conflict with
any obligation of Consultant to a third party or any obligation of Consultant under a contract or other agreement or policy by which Consultant is bound. 

(b)    Consultant represents and warrants that (i) Consultant is authorized to enter int o and perform this
Agreement, and (ii) Consultant is subject to, and shall in the future enter into, no contract or agreement with any person, corporation, government agency or other entity that could, in any manner, impede or prevent Consultant from giving, and
the Company from receiving, the benefit of the Work to be performed under this Agreement. 
 (c)    Consultant
represents and warrants that no information to be disclosed to the Company in performance of this Agreement was or shall be acquired by Consultant (i) pursuant to any relationship in which Consultant was obligated to hold such information in
confidence for the benefit of any third party or (ii) by any unlawful or otherwise improper means. 

(d)    Consultant represents and warrants that no information, materials or other products or results of the Work
delivered to the Company under this Agreement shall infringe upon, conflict with or violate any patent rights, copyrights, trade secrets or other proprietary rights, however denominated, of any person or entity. 

4.    Rights in Intellectual Property. 

(a)    Consultant agrees that all discoveries, developments, inventions, ideas, concepts, research and other information
arising out of any of the Work or use of any Confidential Information or any Materials by or on behalf of Consultant (hereinafter collectively referred to as the “Developments”) shall be the sole property of the Company. Consultant
further agrees that the originals and all copies of all notebooks, disks, tapes, computer programs, reports, proposals and other documents and materials furnished to Consultant by the Company, however and whenever produced (whether by Consultant or
others), shall be the sole property of the Company. 
 (b)    Consultant agrees that all of the Developments, including,
without limitation, all parts thereof, and any memorialization thereof by electronic or manual storage, transcription, or recording, and any display, performance or modification thereof or derivative work based thereon, is work made for hire under
the copyright laws of the United States especially ordered and commissioned by the Company. 
 (c)    Consultant agrees
to and hereby does, assign, to the Company all of Consultant’s right, title and interest throughout the world in all Developments and to anything tangible which evidences, incorporates, constitutes, represents, memorializes, embodies, performs,
displays or records any such Development. Consultant hereby assigns and, to the extent any such assignment cannot be made at present, 

  
 2 

Confidential 

 CONSULTING AGREEMENT 

 

 
Consultant hereby agrees to assign to the Company all copyrights, patents, trademarks and other proprietary rights, however denominated, Consultant may have in any such Developments. 

(d)    Consultant specifically agrees and acknowledges that the foregoing assignment covers all results, outputs and
products of Consultant’s Work for the Company prior to the date hereof, in any capacity and all related copyrights, patents, trademarks or other proprietary rights, however denominated, and that all such results, outputs and products shall be
Developments hereunder and the sole property of the Company. 
 (e)    Consultant hereby undertakes, without payment of
any consideration to Consultant in addition to the compensation described in Section 2(a), (i) promptly to disclose all Developments to the Company; (ii) to assist the Company in every reasonable manner to obtain thereon patents,
copyrights, and other forms of proprietary protections, however denominated, in any and all countries for the Company’s benefit; (iii) to execute all such patent applications, patent or copyright assignments, registrations and applications
that may be required for other forms of proprietary protection, however denominated, and other lawful documents, and to take all such other actions, as the Company may request to obtain for the Company all right, title and interest in and to any of
the Developments or otherwise to carry out the purposes of this Agreement. Without limiting the foregoing, if Consultant is called upon by the Company in writing after termination or expiration of this Agreement or performance of the Work to assist
the Company as provided herein, Consultant shall be entitled to reasonable fees for services rendered in providing such assistance. The out-of-pocket cost of prosecuting
patent applications and obtaining copyright registration shall be borne by the Company. 
 (f)    If Consultant
incorporates into any Developments any information, software, materials or other technology owned by Consultant or in which Consultant has any interest, Consultant hereby grants, and to the extent any such grant cannot be made at the present,
Consultant agrees to grant to the Company a non-exclusive, royalty-free, irrevocable, perpetual, transferable worldwide license, with the right to sublicense, to make, use, refrain from using, sell, offer for
sale, import, modify, delete, add to, reproduce, create derivative works based upon, distribute, perform, display or exploit in any way, such information, software, materials or other technology, in whole or in part, by any means, now known or later
developed, in all languages. 
 (g)    It is understood that Sections 4 and 5 of this Agreement apply, without
limitation, to any and all oral communications and writings, including, without limitation, notes, drawings, specifications, software, source code, object code, schematics, flow charts, algorithms and engineering, sales, marketing and financial
plans, and studies and reports that are prepared, compiled or acquired by Consultant during the term of this Agreement. 

5.    Non-Disclosure and Confidentiality. 

(a)    The Company shall provide Consultant with materials and such information about the Company, its business and its
products and services as the Company, in its sole discretion, shall deem necessary or appropriate to enable Consultant to carry out Consultant’s obligations under this Agreement. 

(b)    Consultant acknowledges that in the course of consulting for the Company, Consultant shall receive materials and
information about, and access to, trade secrets and other confidential and proprietary information (including, without limitation, the information and materials described in Section 4 of this Agreement) which are vital to the competitive
position and success of the Company. During the term of this Agreement and thereafter, Consultant shall hold strictly confidential and shall not disclose to others any of the Confidential Information. Consultant shall not use any of the Confidential
Information or Materials other than as part of the Work and for the sole benefit of the Company. Without 

  
 3 

Confidential 

 CONSULTING AGREEMENT 

 

 
the prior written consent of the Company, (i) Consultant shall not distribute or otherwise allow the release of the Materials to any third party, (ii) Consultant shall not, nor allow or
encourage any third party to, manufacture or analyze or otherwise “reverse engineer” any Materials, and (iii) Consultant shall comply with all laws and regulations regarding the transportation, use and disposal of Materials. 

(c)    The term “Confidential Information” as used throughout this Agreement shall mean all Developments
and all trade secrets, confidential or proprietary information, all information concerning any of the Materials, and other data or information (and any tangible evidence, record or representation thereof), whether prepared, conceived or developed by
an employee or consultant of the Company (including, without limitation, Consultant) or received by the Company from an outside source, which is in the possession of the Company (whether or not the property of the Company) and which is maintained in
secrecy or confidence by the Company or which might permit the Company or any of its customers to obtain a competitive advantage over competitors who do not have access to such Developments, Materials, trade secrets, confidential or proprietary
information or other data or information. The term “Materials” as used throughout this Agreement shall mean all materials provided to Consultant by or on behalf of the Company, all materials derived therefrom, and all Developments
to the extent such Developments constitute tangible materials. 
 (d)    Consultant understands that the Company from
time to time may have in its possession materials and information (including product and development plans and specifications)which is claimed by others to be proprietary and which the Company has agreed to keep confidential. Consultant agrees that
all such materials and information shall be Materials and Confidential Information, respectively, for purposes of this Agreement. 

6.    Non-Competition,
Non-Solicitation. 
 (a)    During the term of this Agreement, Consultant
shall not, directly or indirectly, participate, whether as owner, stockholder, director, officer, manager, employee , agent or consultant or otherwise in any business, firm or corporation which is in competition with the Company, or which otherwise
provides any products or services similar to any products or services provided by the Company at the time of such termination or expiration (collectively, a “Competing Company”). However, the foregoing sentence shall not be
construed to prohibit purchase on a national securities exchange or in the “over-the-counter” market of any securities of a Competing Company listed on such
exchange or publicly traded in such market, provided however. that such purchase does not result in Consultant becoming owner of record of five percent (5%) or more of the outstanding of any class of such company’s securities. 

(b)    During the term of this Agreement and for a period of one year after the termination or expiration hereof,
Consultant shall not solicit or attempt to solicit any employee of the Company (or any other person who may have been employed by the Company during the term of this Agreement) with whom the Consultant had contact during the term of this Agreement
to perform work or services for any person or entity other than the Company. 
 7.    Relationship of the
Parties. In performing the Work under this Agreement, Consultant shall at all times act as an independent contractor. This Agreement shall not create any relationship whereby Consultant shall be an agent or legal representative of the Company
for any purpose whatsoever and creates no relationship of employment, principal and agent, partnership or joint venturers. Consultant shall have no authority to bind the Company or to create any express or implied obligation for the Company, and
shall not hold himself out as having such authority. Consultant shall have full responsibility for payment of, and shall pay, all compensation, social security, unemployment, withholding and other taxes and charges for all persons engaged by him in
the performance of services hereunder, as and when the same become due and 

  
 4 

Confidential 

 CONSULTING AGREEMENT 

 

 
payable, and the Company shall have no obligation to pay or make available any employee benefit to Consultant or any person employed by or associated with Consultant. 

8.    Term and Termination; Effects of Termination. 

(a)    The initial term of this Agreement is twelve (12) months from the Effective Date (the “Initial
Term”), unless earlier terminated as provided below or extended upon mutual agreement of the Company and Consultant. All services performed by Consultant during the Initial Term in excess of four hundred eighty (480) hours must be pre-approved by the President of the Company, and Consultant will be compensated for the excess time and related expenses as set out in Section 2. 

(b)    The Company may terminate this Agreement by sending written notice of termination to Consultant at any time after
Consultant fails or neglects to perform any of Consultant’s obligations hereunder, including, without limitation, the timely performance of the Work, or otherwise after Consultant’s breach of any provision hereof, such notice to be
effective immediately upon sending. 
 (c)    The Company or Consultant may terminate this Agreement at any time prior
to expiration of the Initial Term for its own convenience at any time upon sixty (60) days prior written notice to the other party. Upon any such termination, Consultant will be entitled solely to compensation in accordance with Section 2
hereof for the amount of time worked and expenses incurred in accordance with the terms and conditions of this Agreement through the date of termination. In the event of an early termination by the Company under this Section, such amounts shall be
paid by the Company within ten (10) days after receipt of Consultant’s final invoice. 
 (d)    Upon
termination or expiration of this Agreement, or at any time upon the written request of the Company, Consultant shall return promptly to the Company all Confidential Information and Materials and all other documents, materials and property belonging
to the Company or its clients. If requested to do so by the Company, Consultant shall sign a Termination Certificate in which Consultant confirms that Consultant has complied with the requirements of this Section 8(d) and that Consultant is
aware that certain restrictions imposed upon Consultant by this Agreement shall continue after termination or expiration of this Agreement, provided that Consultant’s obligations under this Agreement shall continue even if Consultant does not
sign such a Termination Certificate. The Company may withhold final payment under this Agreement until its receipt of such a Termination Certificate. 

(e)    Upon the earlier to occur of the termination or expiration of this Agreement or completion of the Work, or at any
other time upon request of the Company, Consultant shall deliver promptly to the Company all Materials, notebooks, disks, tapes, computer programs, reports, proposals, other documents, materials, tools, equipment and other property belonging to the
Company or its customers. 
 (f)    Consultant understands and agrees that Consultant’s obligations under Sections
3, 4, 5, 6, 7 and 9 hereof and this Section 8 shall survive and shall not be affected by any expiration or earlier termination of this Agreement. 

9.    Miscellaneous. 

(a)    Any notice required or permitted to be given under this Agreement shall be given in writing and sent by certified
mail to the party at the address set forth below or to such other address as such party shall have designated in writing: 
  

			
	  If to the Company:	  	Genelux Corporation
		  	3030 Bunker Hill Street, Suite 310

  
 5 

Confidential 

 CONSULTING AGREEMENT 

 

			
		  	San Diego, CA 92109
		  	Attention: President and Chief Executive Officer
		  	Facsimile: 1.858.483.0026
		
	  If to Consultant:	  	Pharmaceutical Research Consulting (PRC)
		  	Kladower Damm 37J
		  	D-14089 Berlin, Germany
		  	Attention: President and Chief Executive Officer

 (b)    This Agreement sets forth the entire agreement and understanding between the
parties with respect to the subject matter hereof, and supersedes all prior oral and written agreements and understandings between them relating thereto. In the event of any inconsistency between this Agreement and any other contract between the
Company and Consultant, the provisions of this Agreement shall prevail. 
 (c)    No waiver or amendment of any of the
provisions of this Agreement shall be binding unless made in writing and signed by the parties. No failure on the part of either party to exercise, or delay in exercising, any right or remedy hereunder shall operate as a waiver thereof, nor shall
any single or partial exercise of any such right or remedy by such party preclude any other or further exercise thereof or the exercise of any other right or remedy. A waiver on one occasion shall not constitute a waiver on any further occasion.

 (d)    This Agreement is personal to Consultant, and Consultant shall not delegate or assign any of Consultant’s
rights, duties or obligations hereunder. Any purported assignment or delegation thereof by Consultant shall be void and ineffective. Consultant shall perform Consultant’s duties and obligations hereunder alone or in cooperation with employees
of the Company only, and shall not retain, or use other persons to assist Consultant, or work with other persons. in performing such duties and obligations. 

(e)    This Agreement shall be binding upon, and inure to the benefit of the parties and their respective heirs, legal
representatives, successors and assigns. 
 (f)    In the event that any provision of this Agreement shall be determined
to be unenforceable by reason of its extension for too great a period of time or over too large a geographic area or over too great a range of activities, it shall be interpreted to extend only over the maximum period of time, geographic area or
range of activities as to which it may be enforceable. If, after application of the immediately preceding sentence, any provision of this Agreement shall be determined to be invalid, illegal or otherwise unenforceable by any court of competent
jurisdiction, the validity, legality and enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this Section 9(f), any invalid, illegal or unenforceable provision of this
Agreement shall be severable, and after any such severance all other provisions hereof shall remain in full force and effect. 

(g)    This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the
State of California, without regard to its principles of conflicts of laws. All litigation arising from or relating to this Agreement shall be filed and prosecuted before any court of competent subject matter jurisdiction in San Diego, California.
Consultant hereby consents to the jurisdiction of such courts over him, stipulates to the convenience, efficiency and fairness of proceeding in such courts, and covenants not to allege or assert the inconvenience, inefficiency or unfairness of
proceeding in such courts. 
 [remainder of this page intentionally left blank] 

  
 6 

Confidential 

 ATTACHMENT A-1 

Dr. Aladar A. Szalay, President and CEO, Genelux Corporation, San Diego, USA. 

Dr. Tony Yu, Vice President of Clinical Trial Operations, Genelux Corporation, San Diego, USA. 

Medical and Clinical Trial Strategy Committee: 

Dr. Yuman Fong, Chief, Gastric & Mixed Tumor Service, Murray F. Brennan, Chair in Surgery, Memorial Sloan Kettering Cancer
Center, New York, USA; Chairperson of Medical and Clinical Trial Strategy Committee, Member of the Scientific Advisory Board and Member of Clinical Advisory and Implementation Board of Genelux Corporation, San Diego, USA. 

Dr. Ulrich Lauer, Senior Physician and Associate Professor at the Medical University Clinic Tübingen, Tübingen, Germany;
Member of Medical and Clinical Trial Strategy Committee of Genelux Corporation, San Diego, USA. 
 Dr. Reinhard von Roemeling,
Vice President of Clinical Development Oncology, Daiichi Sankyo, Inc, New Jersey, USA; Member of Medical and Clinical Trial Strategy Committee and Member of Clinical Advisory and Implementation Board of Genelux Corporation, San Diego, USA 

Clinical Trials: 
  

	1.	 Royal Marsden Phase I Clinical Trial (Intravenous): 

Dr. Kevin Harrington, Senior Lecturer at the Institute of Cancer Research and an Honorary Consultant in Clinical
Oncology, Head and Neck Unit, Principal Investigator of completed Phase I Trial at Royal Marsden Hospital, London, UK. 

Dr. Johann de Bono, Honorary Consultant in Medical Oncology, Professor in Experimental Cancer Medicine and Principal
Investigator of completed Phase I Trial at Royal Marsen Hospital, London, UK. 
 COMPLETED 

 

	2.	 Tübingen Phase I Clinical Trial (Intraperitoneal): 

Prof. Dr. med. Ulrich Lauer, Senior Physician and Associate Professor at the Medical University Clinic
Tübingen, Tübingen, Germany; Member of Medical and Clinical Trial Strategy Committee of Genelux Corporation, San Diego, USA. 

Prof. Dr. med. Michael Bitzer, Senior Physician for Gastroenterology and Intensive Care Medicine, Coordinating
Physician of the Department Gastroenterology and Hepatology within the Center of Gastrointestinal Oncology (ZGO) of the Comprehensive Cancer Center (CCC) Tubingen, Tübingen Germany. 

 

	3.	 UCSD Phase 1 Clinical Trial (Chemotherapy/Radiation Combination Therapy): 

Dr. Loren Mell, Medical Research Director, Radiation Oncology; Co-Director of
the Center for Advanced Radiotherapy Technologies; and Principal Investigator of Phase I Clinical Trial, UC San Diego, San Diego, USA. 

  
 7 

Confidential 

 CONSULTING AGREEMENT 

 

 Dr. Sunil Advani, Assistant Professor, Radiology Oncology; and
Principal Investigator of Phase I Clinical Trial, UC San Diego. San Diego, USA. 
  

	4.	 Memorial Sloan Kettering Phase I Clinical Trial (Intrapleural): 

Dr. Valerie Rusch, Chief, Thoracic Service; Miner Family Chair in Intrathoracic Cancers and Principal Investigator of
Phase I Clinical Trial, Memorial Sloan Kettering, New York, USA. 
 Dr. Lee Krug, Associate Attending Physician,
Thoracic Oncology Service and Principal Investigator of Phase I Clinical Trial, Memorial Sloan Kettering, New York, USA. 

  
 8 

Confidential 

 EXHIBIT A 

Description of Work: 
 The Consultant will devote at
least one week per month to the performance of services to the Company under this Agreement. The Consultant’s duties and responsibilities shall include the following: 
  

	1.	 The Consultant will serve as the Company’s acting Chief Medical Officer. The roles and responsibilities of
this position are comparable to a Chief Medical Officer of an entity comparable to the Company, differentiated by the fact that Consultant is not an employee. 

 

	2.	 The Consultant will serve as a primary advisor on medical issues relating to the Company’s preclinical and
clinical development programs. 

  

	3.	 The Consultant will serve as a global medical expert relating to the Company’s development programs and
will assist the Company in the development of partnerships with institutions, experts, opinion leaders, health ministries and other regulatory authorities for ensuring the development of high quality strategies, clinical plans and protocols.

  

	4.	 The Consultant will assist in the oversight of the Company’s clinical programs on a global basis,
including assuring that clinical activities are consistent with the Company’s objectives and proposed timelines. 

  

	5.	 The Consultant will participate in a variety of other activities relating to the Company’s development
programs. 

  

	6.	 The Consultant will at all times work in a professional and cooperative manner and interact harmoniously with
the individuals listed in Attachment A-1 hereto. 

 Consulting Fees: 

$340 per hour, up to a maximum of $2,720 per day, to be invoiced to the Company on a monthly basis. Payment of undisputed amounts are due within thirty
(30) days after the Company’s receipt of invoice. 

  
 9 

Confidential 

 CONSULTING AGREEMENT 

 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. 
  

									
	COMPANY:	 		 	CONSULTANT
			
	GENELUX CORPORATION	 		 	PHARMACEUTICAL RESEARCH CONSULTING
					
	By:	 	 /s/ A.A. Szalay
	 		 	By:	 	 /s/ Dr. Paul
Scigalla                                        
                      

	Name:	 	A.A. Szalay	 		 	Name:	 	Prof. Dr. med Paul Scigalla
	Title:	 	President and CEO	 		 	Title:	 	President and CEO

  
 10 

Confidential 

 

 
 CONFIDENTIAL 

April 9, 2012 
 Paul Scigalla, MD, PhD 

Professor of Medicine 
 Chief Medical Officer 

Genelux Corporation 
 Kladower Damm 37J 

D - 14089 Berlin 
 Dear Professor Scigalla, 

I am writing to you concerning the change in the form of payment of your advisory position. In contrast to a payment based on a hourly service reimbursement,
you and I discussed the format of a retainer based payment. We also agreed, that your payment will be part cash $16,000 per month (U.S. $), as well as additional stock options currently 50,000 per year (present strike price $3). The options will
vest at the end of each employment year and in the case of early termination, the monthly equivalent until the end of service will be recognized. This agreement is a one year agreement renewable at the end of each service year. 

The monthly service payments starting March 1, 2012 will be transferred to you at the end of each month. The cost of travel and accommodation will be
reimbursed to you at the same time each month based on your submitted original receipts. 
 In closing, I would like to thank you for all your professional
contributions to Genelux Corporation in the past and in the future. 
 Sincerely yours, 

/s/ Aladar A. Szalay 
 Aladar A. Szalay, 

President and CEO, Genelux Corporation 
 University Professor,
University of Würzburg, Germany 
 Professor, Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center, 

University of California, San Diego, USA 
  

	
	Accepted by:
	
	 /s/ Dr. Paul Scigalla

  

					
	 Genelux Corporation
 Research and
Development
 San Diego Science Center
 3030 Bunker Hill Street,
Suite 310
 San Diego, California 92109 USA
	  	 Office of Business and Investor

Relations
 1615 Orange Tree Lane, Suite 203

Redlands, California 92374 USA
 909 307 9300 (tel)
	  	 Product Analysis
 Am Neuland 1

D-82347 Bernried, Germany

+49 8158 9223-0 (tel)

  
 Confidential 

 

 
  

 March 1, 2018 

MEMORANDUM OF UNDERSTANDING 
 This
MEMORANDUM is intended to acknowledge, clarify and further amend the terms of the CONSULTING AGREEMENT (Agreement) entered into between GENELUX CORPORATION (Company) and PHARMACEUTICAL RESEARCH CONSULTING (Consultant) on September l, 2011 (Exhibit
1), as amended by mutual agreement pursuant to letter dated April 9, 2012 from Aladar Szalay to Consultant (Exhibit 2). 
  

	 	1.	 Notwithstanding the language in Exhibit 2, referencing an “employment” year, the relationship between
Company and Consultant has always been, and remains , one of independent contractor, as set forth in section 7 of the Agreement. 

  

	 	2.	 The Agreement, as amended by Exhibit 2, is hereby extended to December 31, 2019, and will terminate on
that date unless renewed or extended by written agreement. At any time prior to termination, the Company or Consultant may terminate the Agreement without cause upon 30 days’ notice to the other party. 

 

	 	3.	 Except as set forth herein, other terms of the Agreement as amended remain in full force and effect including,
but not limited to, Consultant ‘s obligations under sections 3 through 8 of that agreement. 

  

			
	/s/ Thomas Zindrick                             June 2, 2018
	Thomas Zindrick
                                         
     date
	President and CEO
	
	I understand an agree to the above terms,
	
	/s/ Paul Scigalla
                                  June 2, 2018
	Paul Scigalla
                                         
           date
	Pharmaceutical Research Consulting

  

									
		 	 Genelux Corporation
 Research and
Development
 San Diego Science Center

3030 Bunker Hill Street, Suite 310
 San
Diego, California 92109 USA
	 		 	 Office of Business and Investor Relations

1615 Orange Tree Lane, Suite 203
 Redlands, California 92374
USA
 909 307 9300 (tel)
	 	

  
 Confidential 

 

 
  

 EXTENSION OF MEMORANDUM OF UNDERSTANDING (MOU) 

The MOU executed by the parties hereto on June 2, 2018, is hereby extended one year, through December 31, 2020, on the same terms and conditions
contained in the MOU executed on June 2, 2018. 
  

			
	/s/ Thomas Zindrick
                              
12-17-2019
	Thomas Zindrick
                                         
     date
	President and CEO
	
	                                    
                                         
   
	Paul Scigalla
                                         
           date
	Pharmaceutical Research Consulting

  

									
		 	 Genelux Corporation
 Research and
Development
 San Diego Science Center

3030 Bunker Hill Street, Suite 310
 San
Diego, California 92109 USA
	 		 	 Office of Business and Investor Relations

1615 Orange Tree Lane, Suite 203
 Redlands, California 92374
USA
 909 307 9300 (tel)
	 	

  
 ConfidentialEX-10.11

 Exhibit 10.11 

 
 

 
 July 1, 2002 
 Yong
“Tony” Yu, PhD 
 Loma Linda, CA 
 Dear Tony: 

I am writing to provide you with a formal offer of employment with Genelux Corporation. Your appointment with the Company will be as a Research Scientist,
Director of the Imaging Group and will be effective July 1, 2002. Your starting salary will be $75,000 per annum. Of that amount, $40,000 per annum will be in the form of deferred compensation. The amount of deferred compensation that you
accrue will be calculated based on the number of days that you have worked between July 1, 2002 and the date that the Company closes an initial stock offering that raises at least $1.5 million. The number of days of deferred compensation
will then be divided by 365 and multiplied by $40,000. Deferred compensation will be paid to you as a lump sum following the closing of the stock offering described above. 

The Company intends to develop an Employee Stock Option Plan. When the Board has approved the Employee Stock Option Plan, you will be awarded an appropriate
number of Employee Stock Options. You will also be provided with group health coverage starting 90 days after the start date of your employment. As a condition of employment, you will be required to sign a Confidentiality Agreement and Intellectual
Property Agreement. The Company will develop an Employee Handbook and you will be required to comply with the policies in the Employee Handbook. Your employment will be on an “at will” basis” and the term of your agreement will be for
1 year with automatic renewal based on satisfactory job performance. 
 It is a pleasure to have you join the Company and we look forward to the important
contribution you will make to the success of our Company. 
 Sincerely, 
  

	
	/s/ A. Douglas Will, MD, MPH
	
	A. Douglas Will, MD, MPH
	President/CEO

 PO BOX 1855 • MAMMOTH LAKES • 93546 

PHONE: 760-924-5667 • FAX:
760-924-0422 

  
 Confidential 

 

 
  

 December 20, 2005 

Yong A. Yu, PhD 
 3030 Bunker Hill Street, Suite 310 

San Diego, CA 92109 
 Dear Dr. Yu: 

I am pleased to inform you that the management of Genelux Corporation has recommended that your annual salary be raised from $75,000.00 to $95,000.00 as of
January 1, 2006. I am in full support of this recommendation. Further, in the name of the Board Members of Genelux Corporation, I would like to thank you for your leadership and extreme commitment to the goals of our company, for exemplary
scientific and intellectual achievements, and for your unparalleled hard work which contributed significantly to the overall success of Genelux Corporation. We all appreciate and thank you for your contribution. 

Your participation in the Genelux 2006 Restricted Stock and Stock Option Plan will be finalized in the spring of 2006. Your scientific contribution, resulting
in filed patents for Genelux Corporation will be recognized with a bonus in the form of stock options or a restricted stock grant, based on a formula that will be provided to you by February 15, 2006. Of course, the Plan has to be approved by
our board of directors and stockholders and the participation of all grantees under the Plan will be subject to approval by our board of directors. 
 We
are extremely thankful to you for the long-term loan you provided to the Corporation. This loan will be repaid to you by December 31, 2005, based on calculations completed by our accounting firm. 

On a personal note, I am very pleased and extremely proud that one of my closest associates from the university times has become one of the most solid pillars
and a creative scientific leader at Genelux Corporation. 
 In closing, I wish you a happy holiday season, and much success, happiness and health in the New
Year. 
  

	
	Sincerely yours,
	
	/s/ Aladar A. Szalay
	
	Aladar A. Szalay, PhD
	President and CEO

  
 Confidential 

 

 
  

 June 22, 2008 

Dear Dr. Yu, 
 I am pleased to inform you that, based on
your past leadership and solid contributions to the success of Genelux Corporation, I have decided to promote you to Associate Vice President of Preclinical Operations and Preclinical Business Development, starting Sept. 1, 2008. Like always, your
leadership, independent decision-making abilities and sense of responsibility will be even more required for your new position. 
 I would like to ask you
to prepare your budget requirements and submit them to the Office of the Chief Operating Officer, Dr. A. Roeder, to coordinate with Dr. K. Murphy, Chief Strategy Officer. Your salary compensation will be set at appropriately $150,000 per
year, as soon as additional funds are available. Your stock option plan will also be adjusted appropriately. 
 Since you do not have prior formal business
education, the company is recommending that you take an appropriate business management course at the expense of Genelux Corporation to aid your optimal function in championing the preclinical business program of Genelux Corporation. The reporting
structure for you will be established at a later time. However, you will be expected to work harmoniously with Dr. A. Roeder, Dr. J. F. Kapp, Dr. K. Murphy and Dr. N. Chen. 

Your responsibilities as Director of Tumor Diagnosis/Therapy will continue until the appropriate replacement is found, no later than Sept. 1, 2009. Similarly,
your expert handling of the medical and scientific management of the patent portfolio is highly appreciated and will stay under your control until further notice. Similarly, all preclinical experimentation and preclinical services remain under your
direction, as in the past. All other details of your employment remain unchanged at this time. 
 I would like to be the first to congratulate you on this
step up in corporate responsibility and wish you continued success in building an excellent preclinical business inside of Genelux Corporation. 
 Please
indicate your acceptance by signing this letter and returning it to my office. 
 Sincerely yours, 

 

					
	/s/ A. A. Szalay, PhD	 		 	
			
	A. A. Szalay, PhD	 		 	
	Chairman of the Board of Directors	 		 	
	President and CEO	 		 	
	Genelux Corporation	 		 	
		 		 	/s/ Tony Yu 6/27/08
			
		 		 	          Tony Yu

 Genelux Corporation 
  

					
	 	 	 
	 Research and Development
 San Diego
Science Center
 3030 Bunker Hill Street, Suite 310
 San Diego,
California 92109 USA
 858.483.0024 (tel)
 858.483.0026
(fax)
	  	 Office of Business and Investor Relations

1615 Orange Tree Lane, Suite 203
 Redlands, California 92374
USA
 909.307.9300 (tel)
 909.307.2251 (fax)
	  	 Product Analysis
 Am Neuland 1

82347 Bernried, Germany
 +49 8158
9223-0 (tel)
 +49 8158 922335 (fax)

  
 Confidential 

 

 
  

 CONFIDENTIAL 

January 21, 2010 
 Dear Dr. Yu, 

I am pleased to inform you that the management of Genelux Corporation with major input from Members of the Board of Directors selected you for the position of
Vice President of Clinical Trial Operations. This position will commence on January 21, 2010. 
 The Vice President of Clinical Trial Operations
reports to the CEO and to the CSO. The VP of Clinical Trial Operations is also expected to interact closely with the VP of Medical and Clinical Strategies, Dr. Kevin Murphy, who is under the chairmanship of Professor Y. Fong, Medical and
Clinical Strategy Advisory Group, responsible for all medical and clinical strategies. I am requesting the Clinical Trial Operations group never to make any decision in human medical or in clinical matters effecting humans without the written
approval of Dr. Fong, Dr. Murphy and the principal investigators. 
 The VP of Clinical Trial Operations oversees all clinical trial associated
matters, which include preparation of clinical protocols with principal investigators and with the respective regulatory agencies. Further the VP of Clinical Operations is also responsible for all aspects of the activities of the Director of
Clinical Trial Operations, Ms. Terry Chamberlin. Ms. Chamberlin reports directly to the VP of Clinical Trial Operations. In addition, the VP of Clinical Trial Operations is also responsible for preparation of budgets with both the clinical
trial sites, as well as with the CRO’s. The facilitation and documentation of all communication between the office of the VP of Clinical Trial Operations and that of all personnel involved in the trial process is one of the most important
duties of the VP. Concerning the presently ongoing trial at Marsden Hospital, a direct access to all information has to be established for the sponsor institution, Genelux GmbH, represented by Dr. Caroline Staib and Dr. Albert Roeder at
the clinical trial email site, clinicaltrials@genelux.com. 
 Coordinated and well planned interaction is required between the VP of Clinical Trial
Operations and Dr. Caroline Staib, Vice President of Product Development, Scientific & Clinical Liaison regarding the assurance of timely product availability for all protocols and trials. Further a harmonious, constructive and
synergistic interaction is required between the activities of the VP of Clinical Trial Operations and that of the Chairman of the Clinical Strategy Advisory Group, as well as, the VP of Medical and Clinical Strategies on all future planning of
clinical trials. All such proposed plans will be approved by the management of Genelux Corporation with the signatures of the CEO and that of the CFO before initiation of trials spearheaded by the VP of Clinical Trial Operations. 

Genelux Corporation 
  

					
	 	 	 
	 Research and Development
 San Diego
Science Center
 3030 Bunker Hill Street, Suite 310
 San Diego,
California 92109 USA
 858.483.0024 (tel)
 858.483.0026
(fax)
	  	 Office of Business and Investor Relations

1615 Orange Tree Lane, Suite 203
 Redlands, California 92374
USA
 909.307.9300 (tel)
 909.307.2251 (fax)
	  	 Product Analysis
 Am Neuland 1

82347 Bernried, Germany
 +49 8158
9223-0 (tel)
 +49 8158 922335 (fax)

  
 Confidential 

 

 
  

 The activity of the VP of Clinical Trial Operations will be rewarded with a salary of $175,000/per annum
after a six (6) month probationary period ending June 21, 2010, until that time you will remain on your current salary base. Further, as I informed you, the management of Genelux Corporation suggested that you complete one or more
leadership or people skills management training courses including interpersonal skills course, if possible before December 31, 2010 offered at UCSD or an equivalent quality institution. The cost for such training will be borne by Genelux
Corporation. Upon completion of such training courses, an informal, conversation-based evaluation of your performance will be conducted with two (2) members of the Board of Directors of Genelux Corporation and your position as VP of Clinical
Trial Operations extended for an additional two (2) years. The approval will be reflected in elevating your salary to $200,000/per annum by January 1, 2011. All additional benefits offered by Genelux Corporation during your present
employment will continue without change. 
 In the name of the Board of Directors and the management of Genelux Corporation, I welcome you cordially as the
first VP of Clinical Trial Operations of our company. Further, I would like to express my thanks and pride to you that you were the very first employee of Genelux Corporation and deservingly reached this distinguished position with intellect and
hard work on behalf of our shareholders. 
 Sincerely yours, 
  

	
	/s/ Aladar A. Szalay
	
	Aladar A. Szalay, PhD
	President, CEO and CSO of Genelux Corporation
	University Professor, University of Würzburg, Germany
	 Professor, Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center,
University of California, San Diego, USA

  

			
	Accepted by:	 	
                     
                                         
                           

		 	date

 Genelux Corporation 
  

					
	 	 	 
	 Research and Development
 San Diego
Science Center
 3030 Bunker Hill Street, Suite 310
 San Diego,
California 92109 USA
 858.483.0024 (tel)
 858.483.0026
(fax)
	  	 Office of Business and Investor Relations

1615 Orange Tree Lane, Suite 203
 Redlands, California 92374
USA
 909.307.9300 (tel)
 909.307.2251 (fax)
	  	 Product Analysis
 Am Neuland 1

82347 Bernried, Germany
 +49 8158
9223-0 (tel)
 +49 8158 922335 (fax)

  
 Confidential 

 

 
  

 CONFIDENTIAL 

Memorandum 
 FOR IMMEDIATE RELEASE 

 

			
	To:	  	Dr. Tony Yu, Vice President of Clinical Trial Operations
		
	From:	  	A. A. Szalay, President and CEO
		
	Subject:	  	Completion of your promotion to Vice President of Clinical Trial Operations with salary adjustment
		
	Date:	  	December 17, 2010

  
  

Dear Dr. Yu, 
 I am pleased to inform you that the senior
management of Genelux Corporation supported your appointment to Vice President of Clinical Trial Operations as of January 3, 2011 after the expiration of the probationary period and the completion of the required management skill training
courses at UCLA. In addition, your salary will also be adjusted starting January 3, 2011 to the level outlined in my last letter of January 21, 2010. 

In addition, the management also strongly suggests that you together with the other Vice Presidents participate in a high level course for business executives
focused on business negotiation skill development, including negotiation and hosting skills and practices in the United States, Europe and Asia. Such a course will make your upcoming and increasing duties in two or more party negotiations more
successful. 
 This promotion is the result of your successful development of three (3) different clinical trial protocols, negotiating the trial
conditions and harmonious work between you, the Chairman, Members of the Medical Clinical Strategy Committee and the Director of the individual protocols to commence at three (3) very distinguished institutions (MSKCC, University of Tuebingen
– Germany, and Moores Cancer Center – UC San Diego). The performance evaluation committee was also highly complimentary about your leadership in both tumor therapy experiments in mice, as well as your leadership in the patenting process in
interaction with Dr. Stephanie Seidman and colleagues. It is expected that you will continue to actively participate in both activities as much as your time will allow during the year 2011 or until a successful replacement is identified by the
Management. 
 Please allow me to be the first to congratulate you to your promotion and I wish you continued success in your new and growing
responsibilities. For the holidays, I wish you and your family fun, happiness and good health and a very successful New Year. 
 Sincerely yours, 

 

	
	/s/ Aladar A. Szalay, PhD
	
	Aladar A. Szalay, PhD
	President and CEO, Gene Corporation
	University Professor, University of Würzburg, Germany
	 Professor, Department of Radiation Oncology, Rebecca and John Moores Comprehensive Cancer Center,
University of California, San Diego, USA

  

	P.S.	 The remainder of your accrued salary will be transferred to you between January 5 and 25th of 2011 by the business office. 

  
 Confidential 

 

 
  

 Memorandum 
  

			
	To:	  	Tony Yu,
		  	Vice President, Clinical Trials
		
	From:	  	Thomas Zindrick,
		  	President and Chief Executive Officer
		
	Subject:	  	Pay Rate Change
		
	Date:	  	August 15, 2019

  
  

Tony, 
 I am pleased to inform you that in recognition of your
continued and dedicated service to Genelux Corporation, effective August 15, 2019, your salary has been increased to $240,000 annually. 
 On behalf of
Genelux, congratulations! We look forward to sharing future successes. 
 Acknowledged: 

 

	
	 /s/ Tony Yu

	Tony Yu
	Vice President, Clinical Trials

  
 Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]